[Ip-health] China rejects Gilead hepatitis C drug patent -advocacy group
fiar at verizon.net
Fri Jun 19 04:29:10 PDT 2015
I think it is great--except that it is only the pro-drug? What is the pro-drug?
I thought sofosbuvir was the drug and it is converted after administration?
George M. Carter
On Jun 19, 2015, at 12:27 AM, Tahir Amin wrote:
> The application China has rejected was on a so-called prodrug, a chemical
> used to activate Sovaldi's active chemical once it is in the body,
> according to I-MAK.
> Gilead still has a patent in China on sofosbuvir, the main ingredient of
> Sovaldi, a highly effective treatment for hepatitis C which costs $1,000
> per pill in the United States. That adds up to $84,000 for a typical
> 12-week course.
More information about the Ip-health